Trial · NCT07880288
YO® Smartphone Home Sperm Test Versus Manual Semen Analysis in Egyptian Men
NCT07880288, Not applicable, Active not recruiting, Armed Forces College of Medicine, Cairo, Egypt
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. YO® Smartphone Home Sperm Test Versus Manual Semen Analysis in Egyptian Men. Trials, record NCT07880288. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07880288
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- YO® Smartphone Home Sperm Test Versus Manual Semen Analysis in Egyptian Men
- NCT number
- NCT07880288
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 20 participants, actual
- Lead sponsor
- Armed Forces College of Medicine, Cairo, Egypt
- Conditions
- Semen Analysis, Male Infertility
- Interventions
- YO® Home Sperm Test, Manual Semen Analysis (WHO 6th Edition)
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Correlation Between YO® and Manual Motile Sperm Concentration (MSC) | Day 1 (single study visit, within 1 hour of semen sample collection) | Correlation coefficient and agreement (Bland-Altman mean bias and 95% limits of agreement) between motile sperm concentration (million/mL) measured by the YO® Home Sperm Test and MSC calculated from manual semen analysis according to the WHO 6th edition manual. |
| Secondary | Diagnostic Agreement Between YO® and Manual Analysis in Classifying Oligozoospermia and Asthenozoospermia | Day 1 (single study visit, within 1 hour of semen sample collection) | Sensitivity, specificity, positive and negative predictive values, overall accuracy and Cohen's kappa of the YO® Home Sperm Test in classifying samples as oligozoospermic (sperm concentration below 16 million/mL), asthenozoospermic (progressive motility below 30%) or oligoasthenozoospermic, using manual semen analysis according to the WHO 6th edition lower reference limits as the reference standard. |
| Secondary | Agreement in Sperm Concentration Between YO® and Manual Analysis | Day 1 (single study visit, within 1 hour of semen sample collection) | Correlation and agreement between sperm concentration (million/mL) measured by the YO® device and by manual semen analysis. |
| Secondary | Agreement in Total Motility Between YO® and Manual Analysis | Day 1 (single study visit, within 1 hour of semen sample collection) | Correlation and agreement between total sperm motility (%) measured by the YO® device and by manual semen analysis. |
| Secondary | Agreement in Progressive Motility Between YO® and Manual Analysis | Day 1 (single study visit, within 1 hour of semen sample collection) | Correlation and agreement between progressive sperm motility (%) measured by the YO® device and by manual semen analysis. |
| Secondary | Agreement in Progressively Motile Sperm Concentration (PMSC) Between YO® and Manual Analysis | Day 1 (single study visit, within 1 hour of semen sample collection) | Correlation and agreement between PMSC (million/mL) measured by the YO® device and PMSC calculated from manual semen analysis. |
| Secondary | Time to Result | Day 1 (single study visit, within 1 hour of semen sample collection) | Time in minutes from sample liquefaction to availability of the result, for the YO® device and for manual semen analysis. |
| Secondary | Participant Ease of Use and Satisfaction With the YO® Device | Day 1 (single study visit, within 1 hour of semen sample collection) | Participant-reported ease of use and satisfaction with the YO® Home Sperm Test for potential home use, assessed with a short questionnaire. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07880288
GET https://conductscience.org/api/trials/v1/NCT07880288/registered